Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the toxicity and efficacy of docetaxel and cisplatin combination on two schedules in patients with previously untreated, advanced NSCLC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• histologically or cytologically proven non-small cell lung cancer

• no prior chemotherapy or only adjuvant chemotherapy which had been completed >6 months before registration

• ECOG performance status 0 to 2

• measurable lesion(s)

• normal marrow, hepatic and renal functions

• provision of written informed consent

Exclusion Criteria:

• active infection or severe comorbidities

• history of anaphylaxis of any origin